mdlinx mdlinx
Latest (109) Full Text Articles (6313) Focus on Pediatric Article Summary

Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial
The Lancet Oncology,  Clinical Article

Zhang L et al. – Maintenance treatment with gefitinib significantly prolonged progression-free survival compared with placebo in patients from east Asia with advanced NSCLC who achieved disease control after first-line chemotherapy.

Methods

  • Patients were aged 18 years or older, were of east Asian ethnic origin, had a life expectancy of more than 12 weeks, histologically or cytologically confirmed stage IIIb or IV NSCLC, a WHO performance status of 0—2, and had completed four cycles of first-line platinum-based doublet chemotherapy without disease progression or unacceptable toxic effects.
  • Between Sept 28, 2008 and Aug 11, 2009, 296 patients were randomly assigned 1:1 to receive either gefitinib (250 mg per day orally) or placebo (orally) within 3—6 weeks after chemotherapy until progression or unacceptable toxic effects.
  • Randomisation was done via an interactive web response system with computer-generated randomisation codes.
  • Our primary endpoint was progression-free survival assessed in the intention-to-treat population.

Results
  • Progression-free survival was significantly longer with gefitinib (n=148) than with placebo (148) (median progression-free survival 4·8 months [95% CI 3·2—8·5] vs 2·6 months [1·6—2·8]; hazard ratio [HR] 0·42, 95% CI 0·33—0·55; p<0·0001).
  • Adverse events occurred more frequently with gefitinib than with placebo; the most common adverse events of any grade were rash (73 [50%] of 147 in the gefitinib group vs 14 [9%] of 148 in the placebo group), diarrhoea (37 [25%] vs 13 [9%]), and alanine aminotransferase increase (31 [21%] vs 12 [8%]).
  • The most commonly reported grade 3 or 4 adverse event was alanine aminotransferase increase (3 [2%] of 147 in the gefitinib group, none of 148 in the placebo group).
  • Ten of 147 (7%) patients given gefitinib and five of 148 (3%) patients given placebo had serious adverse events.
  • Three deaths were thought to be related to treatment with gefitinib: one from interstitial lung disease; one from lung infection; and one from pneumonia.

Please login or register to follow this author.
Are you sure you want to Unfollow this Author?
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Oncology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Oncology Articles

Last month's top read Top Articles of 2013

1 Coffee intake and gastric cancer risk Cancer Epidemiology, Biomarkers & Prevention, March 20, 2014    Clinical Article

2 Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial The Lancet Oncology, March 7, 2014    Clinical Article

3 Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial The Lancet Oncology, March 11, 2014    Clinical Article

4 Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials The Lancet, March 25, 2014    Evidence Based Medicine    Clinical Article

5 Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): A companion analysis of a randomised controlled trial The Lancet Oncology, March 14, 2014    Clinical Article

6 Chemoradiation therapy versus chemotherapy alone for gastric cancer after R0 surgical resection: A meta-analysis of randomized trials Oncology, February 4, 2014    Evidence Based Medicine    Clinical Article

7 Risk of developing myelodysplastic syndromes in prostate cancer patients definitively treated with radiation Journal of the National Cancer Institute, March 4, 2014    Clinical Article

8 Screening for prostate cancer with the prostate-specific antigen test: A review of current evidence JAMA, March 21, 2014    Evidence Based Medicine    Clinical Article

9 Dietary carrot consumption and the risk of prostate cancer European Journal of Nutrition, February 17, 2014    Clinical Article

10 Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: A meta-analysis of individual patient data The Lancet Oncology, March 7, 2014    Clinical Article

11 A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients Annals of Oncology, February 18, 2014    Clinical Article

12 Radical prostatectomy or watchful waiting in early prostate cancer New England Journal of Medicine, March 10, 2014    Evidence Based Medicine    Clinical Article

13 Coffee consumption and prostate cancer risk: An updated meta-analysis Cancer Causes and Control, March 4, 2014    Evidence Based Medicine    Clinical Article

14 Statins and aspirin for chemoprevention in Barrett's esophagus: Results of a cost-effectiveness analysis Cancer Prevention Research, February 25, 2014    Clinical Article

15 Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): Follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort The Lancet Oncology, March 24, 2014    Clinical Article

16 Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab Journal of Clinical Oncology, March 19, 2014    Clinical Article

17 Tea consumption and leukemia risk: A meta-analysis Tumor Biology, February 13, 2014    Evidence Based Medicine    Clinical Article

18 Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study The Lancet Oncology, March 3, 2014    Clinical Article

19 Yoga’s impact on inflammation, mood, and fatigue in breast cancer survivors: a randomized controlled trial Journal of Clinical Oncology, February 3, 2014    Clinical Article

20 Tumor infiltrating lymphocytes is prognostic and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial Annals of Oncology, March 12, 2014    Clinical Article

Indexed Journals in Oncology: Journal of Clinical Oncology, Cancer Research, Annals Oncologymore

Other Topics in Oncology

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Stay current - Media Tool

Newsletter
RSS
Follow
Like

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Close